Payment overview · 2025
General Payments
$261.24
6 reported records · 2 companies
Healthcare provider profile · identity verified
Luis A Catoni, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAS PIEDRAS, PR · NPI 1780653923
Verified facts
What the public records show
CMS Open Payments records show Luis A Catoni, MD received $261.24 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 86.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 286 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.24 | 86.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.00 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $261.24 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $83.37 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $33.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 151 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
286 | 71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
151 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 963 | 265 |
| Metformin Hcl | Metformin Hcl | 585 | 153 |
| Gabapentin | Gabapentin | 550 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 409 | 116 |
| Famotidine | Famotidine | 352 | 110 |
| Losartan Potassium | Losartan Potassium | 351 | 104 |
| Omeprazole | Omeprazole | 310 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 86 |
| Farxiga | Dapagliflozin Propanediol | 286 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 284 | 87 |
| Fluticasone Propionate | Fluticasone Propionate | 270 | 84 |
| Lisinopril | Lisinopril | 252 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 67 |
| Synthroid | Levothyroxine Sodium | 227 | 62 |
| Clonazepam | Clonazepam | 202 | 32 |
| Candesartan Cilexetil | Candesartan Cilexetil | 195 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 190 | 57 |
| Simvastatin | Simvastatin | 181 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 47 |
| Alendronate Sodium | Alendronate Sodium | 164 | 51 |
| Montelukast Sodium | Montelukast Sodium | 155 | 42 |
| Jardiance | Empagliflozin | 151 | 41 |
| Ezetimibe | Ezetimibe | 146 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 143 | 35 |
| Allopurinol | Allopurinol | 139 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 44 |
| Irbesartan | Irbesartan | 128 | 35 |
| Januvia | Sitagliptin Phosphate | 121 | 30 |
| Chlorthalidone | Chlorthalidone | 120 | 32 |
| Ketoconazole | Ketoconazole | 115 | 43 |
| Enalapril Maleate | Enalapril Maleate | 114 | 27 |
| Baclofen | Baclofen | 107 | 25 |
| Carvedilol | Carvedilol | 107 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 44 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 104 | 31 |
| Eliquis | Apixaban | 97 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 96 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 28 |
| Diclofenac Potassium | Diclofenac Potassium | 88 | 29 |
| Finasteride | Finasteride | 81 | 25 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 78 | 20 |
| Latanoprost | Latanoprost | 78 | 22 |
| Furosemide | Furosemide | 76 | 31 |
| Mometasone Furoate | Mometasone Furoate | 71 | 26 |
| Sertraline Hcl | Sertraline Hcl | 70 | 16 |
| Sucralfate | Sucralfate | 69 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 68 | 22 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 67 | 18 |
| Desonide | Desonide | 67 | 22 |
| Trazodone Hcl | Trazodone Hcl | 67 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 66 | 65 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 21 |
| Desloratadine | Desloratadine | 62 | 18 |
| Spironolactone | Spironolactone | 62 | 14 |
| Ammonium Lactate | Ammonium Lactate | 61 | 33 |
| Calcitriol | Calcitriol | 61 | 17 |
| Trulicity | Dulaglutide | 61 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 31 |
| Pregabalin | Pregabalin | 56 | 15 |
| Ciclopirox | Ciclopirox | 55 | 22 |
| Humulin N | Insulin Nph Human Isophane | 53 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 52 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 47 | 19 |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 43 | 13 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 43 | 13 |
| Sure Comfort | Syringe And Needle,insulin,1ml | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | 14 |
| Methotrexate | Methotrexate Sodium | 37 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 13 |
| Nitroglycerin | Nitroglycerin | 37 | 15 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | 12 |
| Meloxicam | Meloxicam | 35 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | 11 |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | 13 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 13 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Indapamide | Indapamide | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | 19 |
| Lorazepam | Lorazepam | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 21 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 20 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Sulindac | Sulindac | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Hydrocortisone-Acetic Acid | Hydrocortisone/Acetic Acid | 15 | 13 |
| Risperidone | Risperidone | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Advocate Syringes | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Forteo | Teriparatide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.24 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, JARDIANCE, LOKELMA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error